Schizophrenia [[electronic resource] /] / [edited by] Daniel R. Weinberger, Paul J. Harrison

• Pubblicazione: Chichester, West Sussex, UK, : Wiley-Blackwell, 2010
• Edizione: 3rd ed.
• Descrizione fisica: 1 online resource (746 p.)
• Disciplina: 616.89/8; 616.898
• Soggetto topico: Schizophrenia; Psychiatry
• Altri autori: WeinbergerDaniel R (Daniel Roy) HarrisonP. J <1960-> (Paul J.)
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Schizophrenia; Contents; Contributors; Editor ' s Note; Preface to the 3rd edition; Preface to the First Edition; PART 1: Descriptive Aspects; CHAPTER 1: Concept of schizophrenia: past, present, and future; CHAPTER 2: The schizophrenia construct: symptomatic presentation; CHAPTER 3: Child and adolescent schizophrenia; CHAPTER 4: Late - onset schizophrenia; CHAPTER 5: The schizophrenia spectrum personality disorders; CHAPTER 6: The prodrome of schizophrenia; CHAPTER 7: Course and outcome; CHAPTER 8: Neurocognitive impairments in schizophrenia: their character and role in symptom formation ; PART 2: Biological AspectsCHAPTER 9: The secondary schizophrenias; CHAPTER 10: Schizophrenia: the epidemiological horizon; CHAPTER 11: Environmental risk factors for schizophrenia; CHAPTER 12: Classical genetic studies of schizophrenia; CHAPTER 13: Genetic associations in schizophrenia; CHAPTER 14: Intermediate phenotypes in genetic studies of schizophrenia; CHAPTER 15: Electrophysiology of schizophrenia; CHAPTER 16: Structural brain imaging in schizophrenia and related populations; CHAPTER 17: Functional brain imaging in schizophrenia; CHAPTER 18: Neuropathology of schizophrenia ; CHAPTER 19: Neurodevelopmental origins of schizophreniaCHAPTER 20: Dopamine and schizophrenia; CHAPTER 21: Contributions of glutamate and GABA systems to the neurobiology and treatment of schizophrenia; CHAPTER 22: Animal models of schizophrenia; PART 3: Physical Treatments; CHAPTER 23: Pharmacology and neuroscience of antipsychotic drugs; CHAPTER 24: Principles of pharmacological treatment in schizophrenia; CHAPTER 25: Comparative efficacy and effectiveness in the drug treatment of schizophrenia; CHAPTER 26: Approaches to treatment - resistant patients ; CHAPTER 27: Neurological complications of antipsychotic drugsCHAPTER 28: Metabolic adverse effects associated with antipsychotic medications; PART 4: Psychosocial Aspects; CHAPTER 29: Schizophrenia and psychosocial stresses; CHAPTER 30: Mental health services for patients with schizophrenia; CHAPTER 31: Societal outcomes in schizophrenia; CHAPTER 32: Psychological treatment of psychosis; CHAPTER 33: Economics of the treatment of schizophrenia; Index; colour plates
• Sommario/riassunto: Schizophrenia is one of the most complex and disabling diseases to affect mankind. Relatively little is known about its nature and its origins, and available treatments are inadequate for most patients. As a result, there are inevitable controversies about what causes it, how to diagnose it, and how best to treat it. However, in the past decade, there has been an explosion of new research, with dramatic discoveries involving genetic etiology and epidemiological risk factors. There has also been a catalog of new drugs coming to market, and controversy about the relative advantages and disa
• Titolo autorizzato: Schizophrenia
• ISBN: 1-4443-4774-8; 1-283-20486-X; 9786613204868; 1-4443-2729-1; 1-4443-2730-5
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910140881303321
• Lo trovi qui: Univ. Federico II